Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eileen Blasi

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
International Journal of Toxicology|June 4, 2026
Hitching a Ride to Overcome Barriers: Nonclinical Safety Considerations for Bioconjugated OligonucleotidesSheroy Minocherhomji, Katie Sokolowski, Kelle Franklin, et al.
Paediatric Drugs|June 26, 2021
Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion RecommendationsElly Barry, Jaimie A Walsh, Scott L Weinrich, et al.
Journal of Cardiovascular Pharmacology|May 21, 2009
Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressureEileen Blasi, Mark Bamberger, Delvin Knight, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 23, 2013
Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunctionGina M Yanochko, Allison Vitsky, Jonathan R Heyen, et al.
Scientific Reports|February 23, 2019
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugatesMaria José Costa, Jyothirmayee Kudaravalli, Jing-Tyan Ma, et al.
Nucleic Acid Therapeutics|May 30, 2025
Developmental and Reproductive Toxicity Testing Strategies for Oligonucleotides: A Workshop ProceedingsBethany R Hannas, Sara M Bender, Eileen Blasi, et al.
Blood Advances|January 4, 2018
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignanciesShu-Hui Liu, Yin Gu, Bernadette Pascual, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
International Journal of Toxicology|June 4, 2026
Hitching a Ride to Overcome Barriers: Nonclinical Safety Considerations for Bioconjugated OligonucleotidesSheroy Minocherhomji, Katie Sokolowski, Kelle Franklin, et al.
Paediatric Drugs|June 26, 2021
Navigating the Regulatory Landscape to Develop Pediatric Oncology Drugs: Expert Opinion RecommendationsElly Barry, Jaimie A Walsh, Scott L Weinrich, et al.
Journal of Cardiovascular Pharmacology|May 21, 2009
Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressureEileen Blasi, Mark Bamberger, Delvin Knight, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 23, 2013
Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunctionGina M Yanochko, Allison Vitsky, Jonathan R Heyen, et al.
Scientific Reports|February 23, 2019
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugatesMaria José Costa, Jyothirmayee Kudaravalli, Jing-Tyan Ma, et al.
Nucleic Acid Therapeutics|May 30, 2025
Developmental and Reproductive Toxicity Testing Strategies for Oligonucleotides: A Workshop ProceedingsBethany R Hannas, Sara M Bender, Eileen Blasi, et al.
Blood Advances|January 4, 2018
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignanciesShu-Hui Liu, Yin Gu, Bernadette Pascual, et al.
Pageof 1